Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568267 · ClinicalTrials.gov registry record · Phase 2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
A Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 534
- Enrollment target
- 20
- Study locations
NCT02568267: Active Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
NCT02568267 is a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 534 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02568267, a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 534 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Primary Outcome
Assessed by blinded independent central review (BICR) using RECIST v1.1
Conditions Studied
Interventions
- DRUG Entrectinib
Study Locations (20)
California
- City of Hope Cancer Center - Duarte
- City of Hope Duarte - Comprehensive Cancer Center, Investigational Drug Services - Duarte
- Scripps Clinic - La Jolla
- University of California San Diego Moores Cancer Center - La Jolla
- Southern California Kaiser Permanente - Los Angeles
- University of Southern California Medical Center - Los Angeles
- Univ Of California Irvine College Of Medicine - Orange
- UCSF Mount Zion Medical Ctr - San Francisco
- UCSF Mission Bay - San Francisco
- Sarcoma Oncology Center - Santa Monica
- Sarcoma Oncology Research Center LLC - Santa Monica
Florida
- Florida Cancer Specialists - Sarasota - Sarasota
- H. Lee Moffitt Cancer Center and Research Inst. - Tampa
- Moffitt Cancer Center - Tampa
Arizona
- Dignity Health St Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - Phoenix
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University - New Haven
District of Columbia
- Georgetown University Medical Center Lombardi Cancer Center - Washington D.C.
Georgia
- University Cancer & Blood Center, LLC - Athens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2015-11-19 |
| Est. Completion | 2026-05-14 |
| Phase | Phase 2 |
What the registry record for NCT02568267 still lists
NCT02568267 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (81% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Entrectinib is the first listed.
NCT02568267 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02568267 about?
NCT02568267 is a clinical study titled "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)". This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
What is the current status of trial NCT02568267?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 534 participants. The study started on 2015-11-19. Estimated completion is 2026-05-14.
What conditions does trial NCT02568267 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT02568267?
The interventions under investigation include: Entrectinib (DRUG).
Who is sponsoring clinical trial NCT02568267?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568267 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02568267's enrollment target sits among peer trials
534 186th of 1224 higher than 1,039 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI